Literature DB >> 16044058

A double-blind, randomized, placebo-controlled trial of prilocaine and felypressin (Citanest and Octapressin) for the relief of pain associated with cervical biopsy and treatment with the Semm coagulator.

Ian D Duncan1, Carolyn A McKinley, Sheena B Pinion, Sheena M Wilson.   

Abstract

OBJECTIVE: To quantify the anticipated and actual pain experienced in association with preliminary cervical punch biopsies and subsequent ablative treatment with the Semm coagulator, and to test the hypothesis that the intracervical injection of prilocaine with felypressin reduces the intensity of the pain experienced.
MATERIALS AND METHODS: One hundred consecutive women referred with abnormal cervical smears for colposcopic assessment and considered suitable for treatment with the Semm coagulator were recruited to a double-blind, randomized, prospective, placebo-controlled trial conducted in a colposcopy clinic in a university teaching hospital. Personal particulars were taken and anticipated pain scored. The patients were injected with randomized externally identical vials of prilocaine and felypressin (Citanest and Octapressin) or placebo. After biopsy and treatment, patients scored their actual pain experienced. Pain scores were compared as the main outcome measure. Relative risks with 95% CIs were calculated and compared using the CI Analysis computer programme (Professor Martin J Gardner and the British Medical Journal Version 1.1, copyright 1991).
RESULTS: Anticipated pain was greater than the actual pain experienced in both groups. Women receiving the local anesthesia experienced a significantly greater reduction in pain (p < .05) with only 4.3% and 6.7% experiencing moderate pain during biopsy and treatment, respectively. The active drug abolished severe pain. In the placebo group, 44.7% felt mild pain at the most.
CONCLUSIONS: Intracervical injection of prilocaine and felypressin reduces the intensity of pain experienced in women undergoing cervical biopsy and treatment with the Semm coagulator. Its use is commendable but is not absolutely necessary in all cases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16044058     DOI: 10.1097/01.lgt.0000171663.86847.45

Source DB:  PubMed          Journal:  J Low Genit Tract Dis        ISSN: 1089-2591            Impact factor:   1.925


  6 in total

Review 1.  Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment.

Authors:  Ketan Gajjar; Pierre P L Martin-Hirsch; Andrew Bryant; Gemma L Owens
Journal:  Cochrane Database Syst Rev       Date:  2016-07-18

2.  Feasibility of thermocoagulation in a screen-and-treat approach for the treatment of cervical precancerous lesions in sub-Saharan Africa.

Authors:  Manuela Viviano; Bruno Kenfack; Rosa Catarino; Eveline Tincho; Liliane Temogne; Anne-Caroline Benski; Pierre-Marie Tebeu; Ulrike Meyer-Hamme; Pierre Vassilakos; Patrick Petignat
Journal:  BMC Womens Health       Date:  2017-01-07       Impact factor: 2.809

3.  Health Outcomes at 1 Year After Thermal Ablation for Cervical Precancer Among Human Papillomavirus- and Visual Inspection With Acetic Acid-Positive Women in Honduras.

Authors:  Rose C Slavkovsky; Pooja Bansil; Manuel A Sandoval; Jacqueline Figueroa; Doris M Rodriguez; Jose Saul Lobo; Jose A Jeronimo; Silvia de Sanjosé
Journal:  JCO Glob Oncol       Date:  2020-10

Review 4.  Ablative Therapies for Cervical Intraepithelial Neoplasia in Low-Resource Settings: Findings and Key Questions.

Authors:  Miriam L Cremer; Gabriel Conzuelo-Rodriguez; William Cherniak; Thomas Randall
Journal:  J Glob Oncol       Date:  2018-10

5.  Acceptability and safety of thermal ablation for the treatment of precancerous cervical lesions in Honduras.

Authors:  Manuel Sandoval; Rose Slavkovsky; Pooja Bansil; Jose Jeronimo; Jeanette Lim; Jacqueline Figueroa; Silvia de Sanjose
Journal:  Trop Med Int Health       Date:  2019-11-21       Impact factor: 2.622

6.  Acceptability and safety of thermal ablation to prevent cervical cancer in sub-Saharan Africa.

Authors:  Tania Metaxas; Bruno Kenfack; Jessica Sormani; Eveline Tincho; Sophie Lemoupa Makajio; Ania Wisniak; Pierre Vassilakos; Patrick Petignat
Journal:  BMC Cancer       Date:  2022-02-02       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.